Radiopharm Theranostics Ltd (RADX) Enterprise Value (2023 - 2025)
Radiopharm Theranostics (RADX) posted quarterly Enterprise Value of -$198770.8 for Q2 2025, down 55.92% year-over-year from -$450917.0 in Q2 2024, and down 55.92% quarter-over-quarter from -$127483.8 in Q2 2024.
Radiopharm Theranostics Ltd (RADX) Enterprise Value (2023 - 2025) Analysis & Trends
Radiopharm Theranostics (RADX) has reported Enterprise Value for 3 consecutive years, with -$198770.8 the latest figure, recorded in Q2 2025.
- In Q2 2025, Enterprise Value fell 55.92% year-over-year to -$198770.8; the TTM figure through Jun 2025 stood at -$198770.8 (down 55.92% YoY), while the FY2025 annual figure was -$11.9 million, down 54.35% from the prior year.
- Enterprise Value fell to -$198770.8 in Q2 2025 per RADX's latest filing, from -$127483.8 in the prior quarter.
- Across five years, Enterprise Value topped out at -$127483.8 in Q2 2024 and bottomed at -$11.7 million in Q2 2023.
- Historically, Enterprise Value has averaged -$4.0 million across 3 years, with a median of -$198770.8 in 2025.
- Annual changes were most pronounced in 2024 — Enterprise Value jumped 98.91% — and 2025, when it tumbled 55.92%.
- Radiopharm Theranostics' Enterprise Value stood at -$11.7 million in 2023, then surged by 98.91% to -$127483.8 in 2024, then sank by 55.92% to -$198770.8 in 2025.
- Business Quant data shows RADX's Enterprise Value at -$198770.8 in Q2 2025, -$127483.8 in Q2 2024, and -$11.7 million in Q2 2023.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -198,770.84 |
| Jun 30, 2024 | -127,483.78 |
| Jun 30, 2023 | -11.70 Mn |